News
Keyword Search
| Date | Title | Teaser | |
|---|---|---|---|
|
03/09/23
|
Summary ToggleIridex Reports Fourth Quarter and Full Year 2022 Financial Results | Achieves Record Quarterly Glaucoma Probe Sales and 6% Full Year Revenue Growth MOUNTAIN VIEW, Calif. , March 09, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today |
|
|
03/07/23
|
Summary ToggleIridex to Present at the 35th Annual Roth Conference | MOUNTAIN VIEW, Calif. , March 07, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming 35 th Annual Roth Conference in |
|
|
03/02/23
|
Summary ToggleIridex Introduces New Research and Showcases Five Events at the AGS Meeting | Five Events at Booth #5 Discover the latest surgical techniques and outcomes published by the International MicroPulse TLT Consensus Panel . Watch Dr. Syril Dorairaj’s e-poster on prospective MicroPulse TLT dosimetry research outcomes. Demo Sweep Management Software for MicroPulse TLT. |
|
|
02/23/23
|
Summary ToggleIridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023 | MOUNTAIN VIEW, Calif. , Feb. 23, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter and |
|
|
01/10/23
|
Summary ToggleIridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022 | Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue Growth MOUNTAIN VIEW, Calif. , Jan. 10, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today |
|
